Tek doz Biontech/Pfizer aşısının etkisi delta varyantına karşı % 35,5, B.1.1.7 varyantına karşı ise % 51,1. İki dozdan sonra İngiltere varyantına karşı % 87,9, B.1.617.2.varyantına karşı ise % 59,8 olarak saptandı. çalışma;
(not: B.1.1.7 varyantı İngiltere, B.1.617.2. Hindistan varyantı olarak basında geçmektedir)
Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
Results Effectiveness was notably lower after 1 dose of vaccine with B.1.617.2 cases 33.5% (95%CI: 20.6 to 44.3) compared to B.1.1.7 cases 51.1% (95%CI: 47.3 to 54.7) with similar results for both vaccines. With BNT162b2 2 dose effectiveness reduced from 93.4% (95%CI: 90.4 to 95.5) with B.1.1.7 to 87.9% (95%CI: 78.2 to 93.2) with B.1.617.2. With ChAdOx1 2 dose effectiveness reduced from 66.1% (95% CI: 54.0 to 75.0) with B.1.1.7 to 59.8% (95%CI: 28.9 to 77.3) with B.1.617.2. Sequenced cases detected after 1 or 2 doses of vaccination had a higher odds of infection with B.1.617.2 compared to unvaccinated cases (OR 1.40; 95%CI: 1.13-1.75).
Conclusions After 2 doses of either vaccine there were only modest differences in vaccine effectiveness with the B.1.617.2 variant. Absolute differences in vaccine effectiveness were more marked with dose 1. This would support maximising vaccine uptake with two doses among vulnerable groups.
